Research & Development

Research & Development Overview

We are generating several families of anticancer drugs that act on the cell cycle, including Cyclin Dependent kinase (CDK) and Aurora Kinase (AK) inhibitors. Our orally available nucleoside acts through a dual mechanism, interfering with DNA synthesis by causing single-strand DNA breaks and inducing arrest of cell cycle progression mainly at G2-Phase. We are advancing three of our anticancer drug candidates, sapacitabine, seliciclib and CYC116 through in-house research and development activities. We have eight further novel drug series, five for cancer, one for inflammatory kidney disease, one for HIV/AIDS and one for Type 2 Diabetes.

Clinical Drug Pipeline